NZ584640A - Use of a plasminogen activator (desmoteplase) in the treatment of stroke - Google Patents

Use of a plasminogen activator (desmoteplase) in the treatment of stroke

Info

Publication number
NZ584640A
NZ584640A NZ584640A NZ58464008A NZ584640A NZ 584640 A NZ584640 A NZ 584640A NZ 584640 A NZ584640 A NZ 584640A NZ 58464008 A NZ58464008 A NZ 58464008A NZ 584640 A NZ584640 A NZ 584640A
Authority
NZ
New Zealand
Prior art keywords
desmoteplase
treatment
stroke
plasminogen activator
cerebral
Prior art date
Application number
NZ584640A
Other languages
English (en)
Inventor
Mariola Sohngen
Alice Ebel
Yasir Alaa Shafeek Al-Rawi
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ584640(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07020401A external-priority patent/EP2050462A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NZ584640A publication Critical patent/NZ584640A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ584640A 2007-10-18 2008-10-20 Use of a plasminogen activator (desmoteplase) in the treatment of stroke NZ584640A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07020401A EP2050462A1 (en) 2007-10-18 2007-10-18 Improved treatment of stroke patients
EP07022867 2007-11-26
EP08017954 2008-10-15
PCT/EP2008/008871 WO2009049914A2 (en) 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis

Publications (1)

Publication Number Publication Date
NZ584640A true NZ584640A (en) 2012-10-26

Family

ID=40567844

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ584640A NZ584640A (en) 2007-10-18 2008-10-20 Use of a plasminogen activator (desmoteplase) in the treatment of stroke

Country Status (28)

Country Link
US (2) US20100272704A1 (https=)
EP (1) EP2211898B1 (https=)
JP (2) JP5509085B2 (https=)
KR (1) KR20100089077A (https=)
CN (1) CN101903039B (https=)
AR (1) AR068914A1 (https=)
AU (1) AU2008314048B2 (https=)
BR (1) BRPI0817785A2 (https=)
CA (1) CA2702378A1 (https=)
CL (1) CL2009000752A1 (https=)
CY (1) CY1118417T1 (https=)
DK (1) DK2211898T3 (https=)
EA (1) EA020776B1 (https=)
ES (1) ES2611155T3 (https=)
HR (1) HRP20170001T1 (https=)
HU (1) HUE032867T2 (https=)
IL (1) IL205175A0 (https=)
LT (1) LT2211898T (https=)
MX (1) MX2010004157A (https=)
MY (1) MY159200A (https=)
NZ (1) NZ584640A (https=)
PL (1) PL2211898T3 (https=)
PT (1) PT2211898T (https=)
RS (1) RS55590B1 (https=)
SI (1) SI2211898T1 (https=)
TW (1) TWI482628B (https=)
WO (1) WO2009049914A2 (https=)
ZA (1) ZA201002548B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
DK176140B1 (da) * 1988-07-20 2006-09-25 Schering Ag Patentabteilung Flagermusspyt-plasminogenaktivatorer
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
DE59204945D1 (de) * 1991-04-16 1996-02-15 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
ES2107790T3 (es) * 1992-12-04 1997-12-01 Schering Ag Inhibidor de trombina procedente de la saliva de protostomias.
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6354999B1 (en) * 2000-01-14 2002-03-12 Florence Medical Ltd. System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080213244A1 (en) * 2003-05-05 2008-09-04 Wolfgang Sohngen Glutamate Receptor Antagonists as Neuroprotectives
US20050085478A1 (en) * 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途

Also Published As

Publication number Publication date
US20100272704A1 (en) 2010-10-28
JP5509085B2 (ja) 2014-06-04
CL2009000752A1 (es) 2009-12-04
ES2611155T3 (es) 2017-05-05
ZA201002548B (en) 2011-06-29
EP2211898B1 (en) 2016-12-07
US20140314736A1 (en) 2014-10-23
HK1151233A1 (en) 2012-01-27
CN101903039B (zh) 2014-04-02
BRPI0817785A2 (pt) 2015-03-24
HUE032867T2 (en) 2017-11-28
KR20100089077A (ko) 2010-08-11
EA020776B1 (ru) 2015-01-30
CN101903039A (zh) 2010-12-01
DK2211898T3 (en) 2017-01-30
IL205175A0 (en) 2010-11-30
EA201070485A1 (ru) 2010-10-29
AU2008314048A1 (en) 2009-04-23
HRP20170001T1 (hr) 2017-02-24
WO2009049914A3 (en) 2009-08-06
CY1118417T1 (el) 2017-06-28
LT2211898T (lt) 2017-01-25
JP2011500617A (ja) 2011-01-06
AU2008314048B2 (en) 2013-07-25
MY159200A (en) 2016-12-30
TW200927164A (en) 2009-07-01
AR068914A1 (es) 2009-12-16
EP2211898A2 (en) 2010-08-04
SI2211898T1 (sl) 2017-02-28
TWI482628B (zh) 2015-05-01
PT2211898T (pt) 2017-01-31
PL2211898T3 (pl) 2017-03-31
MX2010004157A (es) 2010-04-30
WO2009049914A2 (en) 2009-04-23
CA2702378A1 (en) 2009-04-23
RS55590B1 (sr) 2017-06-30
JP2014065739A (ja) 2014-04-17

Similar Documents

Publication Publication Date Title
Palmer et al. Traumatic coagulopathy‐Part 2: resuscitative strategies
EP4548972A3 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
MX2012001339A (es) Compuestos inhibidores de apaf-1.
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
JP2014240389A5 (https=)
ATE476972T1 (de) Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris
UA88257C2 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ С-α ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ПОЧЕК, КОТОРЫЕ ПРИВОДЯТ К ПРОТЕИНУРИИ, И ДИАБЕТИЧЕСКИМ РЕТИНОПАТИИ, НЕВРОПАТИИ ИЛИ НЕФРОПАТИИ
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
WO2007117981A3 (en) Selective hydroxamate based mmp inhibitors
MY148893A (en) Combination of an hdac inhibitor and an antimetabolite
PH12015500434B1 (en) Combination of sglt2 inhibitors and anti-hypertensive drugs
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR052565A1 (es) Prevencion y tratamiento de trastornos tromboembolicos
Banerjee et al. Intraoperative pharmacotherapeutic blood management strategies in total knee arthroplasty
DE502004003694D1 (de) Phosphodiesterase-5-inhibitoren zur prophylaxe und/oder therapie der portalen hypertonie
NZ584640A (en) Use of a plasminogen activator (desmoteplase) in the treatment of stroke
AR120867A1 (es) Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina
ZA202210111B (en) Anti-coronavirus effect and application of pi4k inhibitor
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
MY148565A (en) Agent for therapy and/or improvement of disseminated intravascular coagulation
WO2023166492A3 (en) Dual inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
UA122847C2 (uk) Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: H. LUNDBECK A/S, DK

Free format text: OLD OWNER(S): PAION DEUTSCHLAND GMBH

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 OCT 2015 BY CPA GLOBAL

Effective date: 20130328

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2016 BY CPA GLOBAL

Effective date: 20150904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2017 BY CPA GLOBAL

Effective date: 20160909

LAPS Patent lapsed